Virtual menopause care clinic Midi Health has expanded its services to include testosterone hormone therapy for women, responding to demand from its patient base. The company now offers the treatment in 12 states, with plans for nationwide expansion as state regulations permit.
The service provides access to a topical cream formulation designed for women, delivered through clinician-led care with personalized dosing. Midi developed the offering to address a regulatory gap in the United States, where no FDA-approved testosterone therapies exist for women, despite decades of use in countries including Australia and the United Kingdom.
“The fact there’s still no FDA-approved option for women in the U.S. is a glaring inequity that leaves millions suffering in silence,” Joanna Strober, CEO and co-founder of Midi Health, stated in the press release. “Our offering provides ongoing care from clinicians who personalize treatment plans and check in regularly to ensure women are getting the results and support they need, all while being covered by insurance.”
Testosterone plays a role in maintaining libido, energy, mood and cognitive function in women. Without approved products, women in the United States must rely on off-label or compounded formulations originally developed for men.
“The reality is that for women who struggle with symptoms that other treatments don’t fully address, testosterone is an evidence-based therapy that can provide the final piece of the puzzle,” Kathleen Jordan, chief medical officer at Midi Health, stated in the press release.
The service is covered by major insurance providers and includes required lab work and ongoing clinical monitoring. Midi has trained licensed providers across its 12 operating states to deliver the therapy. The company uses a topical cream format rather than implanted pellets to allow for dosing adjustments.
